Oxford BioTherapeutics Adds New Board Member
This article was originally published in Scrip
Oxford BioTherapeutics has appointed Shawn Tomasello to its board of directors. Previously she was chief commercial officer of Pharmacyclics and before this she was president of the Americas, hematology and oncology for Celgene Corp. Previously, Tomasello was national director of hematology for Rituxan at Genetech.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.